UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
June 7, 1999
---------------
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11353 13-3757370
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
-------------------------------------------------------
(Address of principal executive offices)
336-229-1127
------------
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS
On June 7, 1999, the Company issued a press release
announcing that its Board of Directors has declared
dividends on the Company's 8 1/2% Series A Convertible
Exchangeable Preferred Stock and the Company's 8 1/2% Series
B Convertible Pay-in-Kind Preferred Stock.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS
(c) Exhibit
20 Press release of the Company dated
June 7, 1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Registrant)
By:/s/ BRADFORD T. SMITH
------------------------------
Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer
Date: June 10, 1999
<PAGE>
2
Laboratory Corporation of America-Registered Trademark- Holdings
358 South Main Street
Burlington, NC 27215
FOR IMMEDIATE RELEASE
- ---------------------
CONTACT: 336-584-5171 SHAREHOLDER DIRECT: 800-LAB-0401
- ------- ------------------
MEDIA - CYNTHIA JAY, EXT. 5052 WWW.LABCORP.COM
INVESTORS - PAMELA SHERRY, EXT. 4855
LABORATORY CORPORATION OF AMERICA-REGISTERED TRADEMARK- DECLARES
PREFERRED STOCK DIVIDENDS
BURLINGTON, NC, JUNE 7, 1999 - Laboratory Corporation of America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-) (NYSE:LH)
today announced that its Board of Directors has declared a dividend of
$1.0625 per share on the Company's 8 1/2 percent Series A Convertible
Exchangeable Preferred Stock (Series A Preferred Stock), payable in cash.
The Board has also declared a dividend of $1.0625 per share on the Company's
8 1/2 percent Series B Convertible Pay-in-Kind Preferred Stock (Series B
Preferred Stock), payable in shares of Series B Preferred Stock at the rate
of 0.02125 shares per share of Series B Preferred Stock held. No fractional
shares of Series B Preferred Stock will be issued, so that the number of
shares to be paid as a dividend on the Series B Preferred Stock will be
rounded to the nearest whole number of shares. The dividends will be payable
on June 30, 1999, for each issued and outstanding share of Series A and
B Preferred Stock to stockholders of record on June 18, 1999, and
will cover the dividend period from April 1, 1999, to June 30, 1999,
at an equivalent annualized rate of $4.25 per share.
Laboratory Corporation of America-Registered Trademark- Holdings
(LabCorp-Registered Trademark-) is a national clinical laboratory
with annual revenues of $1.6 billion in 1998. With 18,000 employees
and over 100,000 clients nationwide, the company offers more than
2,000 clinical tests, ranging from simple blood analyses to more
sophisticated technologies. Included in LabCorp's network of 25 major
laboratories are three Centers of Excellence. The Center for
Molecular Biology and Pathology, in Research Triangle Park (RTP),
North Carolina, develops applications for polymerase chain reaction
(PCR) technology. Its Center for Occupational Testing in RTP is the
world's largest substance abuse testing facility, and the Center for
Esoteric Testing in Burlington, North Carolina, performs the largest
volume of rare analyses in the network. LabCorp's clients include
physicians, state and federal governments, managed care organizations,
hospitals, clinics, long-term care facilities, companies, and other clinical
laboratories.
